# Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis

> **NCT01077531** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 12 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Otelixizumab
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT01077531
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04-28
- **Primary completion:** 2013-03-19
- **Final completion:** 2013-03-19
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The risk-benefit ratio for patients has changed since we initiated the study, and that the study in its current form cannot be justified
- **Last updated:** 2017-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01077531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01077531, "Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01077531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*